sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_526> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_526> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01232> ;
    a rdf:Statement ;
    rdfs:label "invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1 in a randomized double blind clinical study nv14256 in zidovudine experienced hiv infected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aids defining events or death furthermore in a randomized study actg229 nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 6 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of care saquinavir gel capsule 1 mg twice daily coadministered with ritonavir 1 mg twice daily was studied in a heterogeneous population of 148 hiv infected patients maxcmin 1 study at baseline 42 were treatment naive and 1 6 were treatment experienced of which 52 had an hiv rna level 4 copies ml at baseline results showed that 91 148 61 subjects achieved and or sustained an hiv rna level 4 copies ml at the completion of 48 weeks" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01232> bl:category bl:Drug .
}